Iovance Biotherapeutics Inc (IOVA): FY26 guidance raise supports near-term Amtagvi launch momentum, but UBS remains Neutral on Iovance

Overview

This First Read assesses Iovance's increased FY26 guidance, its implications for the Amtagvi launch, and upcoming clinical catalysts. UBS sees the revised outlook as incrementally positive but maintains that the investment thesis relies on revenue acceleration from 2027 onward.

Core views

Iovance raised FY26 revenue guidance to US$410-420m from US$350-370m. The US$415m midpoint is above UBS's US$405m estimate and the US$397m consensus estimate. Assuming FY26 Proleukin sales of US$64m, or roughly 15% of total revenue, UBS calculates that the midpoint implies about 160 patients infused in 3Q and 168 in 4Q—six to eight more than UBS and consensus had anticipated. UBS interprets the increase as management confidence in continued second-half Amtagvi growth, following 2Q momentum from improved patient demand, lower patient attrition and more authorized treatment-center activations. Because management has visibility into enrollment trends and therefore likely into 3Q and potentially 4Q revenue, UBS believes the company can meet the new guidance. UBS nevertheless characterizes the guidance revision as only incrementally positive. It may have supported near-term share-price upside, but the firm says its central thesis remains the prospect of revenue acceleration in 2027 and beyond. It seeks greater clarity over the next several quarters on authorized treatment-center activation and ramp-up, as well as referral patterns, to judge whether that acceleration is developing. The report identifies several potential late-2026 clinical catalysts. UBS expects updated Phase 2 Amtagvi data in second-line and later nonsquamous NSCLC potentially in 4Q26, although management has not guided to timing. Based on prior discussions, UBS expects data from about 80 patients and focuses on whether objective response rate remains around 25% and whether median duration of response exceeds 12 months. It views durability as the key differentiation versus standard-of-care chemotherapy plus immunotherapy or chemotherapy alone, which it says have roughly three to four months median duration of response. Consistent response rates and durable responses could support a planned 2027 supplemental BLA filing and a possible accelerated-approval route, while expanding Amtagvi's addressable market in an indication with high unmet need. At ESMO in October, Iovance is also expected to update first-line melanoma data for Amtagvi plus pembrolizumab and second-line-plus sarcoma data for Amtagvi monotherapy. UBS expects these updates to be incremental. The October 23 IOV-COM-202 update may provide added information on onset, depth and durability of response relevant to the ongoing global Phase 3 TILVANCE-301 trial. The October 26 sarcoma update is expected to provide longer follow-up from the first six enrolled patients, among whom prior data showed a 50% ORR. UBS maintains a Neutral 12-month rating and a US$7.00 price target. Its valuation uses a 2.4x enterprise-value-to-2030 estimated peak-sales multiple, supported by discounted cash flow analysis. The report's forecast-return table shows a -36.3% forecast stock return, comprising -36.3% forecast price appreciation and no dividend yield, versus a 9.9% market return assumption.

Analysis framework

UBS links the raised revenue outlook to implied patient infusion volumes after allowing for Proleukin sales, then assesses whether demand, attrition, treatment-center activation and enrollment trends support execution. It separately evaluates upcoming clinical datasets by response rate and response durability, relates them to regulatory and market-expansion potential, and values the company using an EV-to-peak-sales multiple supported by DCF.

Methodology notes

• Valuation methodsEV/EBITDA valuation

  Enterprise-value-to-peak-sales multiple valuation

  UBS applies a 2.4x enterprise-value-to-2030 estimated peak-sales multiple to set its price target; although the report uses peak sales rather than EBITDA, this is an enterprise-value multiple approach.

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow support

  UBS states that its peak-sales multiple valuation is supported by DCF analysis.

• Industry AnalysisVolume-price decomposition

  Revenue-to-patient-infusion bridge

  The report derives implied quarterly patient infusion volumes from the FY26 revenue-guidance midpoint after assuming Proleukin sales, using the result to assess launch momentum.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Iovance Biotherapeutics Inc (IOVA.US)

  Primary covered biotechnology company; its Amtagvi launch execution and pipeline data drive the report's outlook.

  Strengths

  Raised FY26 guidance, improving demand, reduced patient attrition, increased treatment-center activations, and potential durable NSCLC responses.

  Weaknesses

  The longer-term case depends on revenue acceleration from 2027 and additional evidence on treatment-center ramp and referrals.

  Comparison

  UBS contrasts potential Amtagvi NSCLC durability of more than 12 months with roughly three to four months median duration of response for chemotherapy plus immunotherapy or chemotherapy alone.

  Risks

  Commercial execution, pipeline trial failure, regulatory changes or additional requirements, and greater competition in melanoma and NSCLC.

Key data

• FY26 revenue guidanceUS$410-420mRaised from US$350-370m; US$415m midpoint versus UBS US$405m and consensus US$397m.
• Assumed FY26 Proleukin salesUS$64mApproximately 15% of total revenue in UBS's implied infusion calculation.
• Implied Amtagvi patients infused~160 in 3Q26 and ~168 in 4Q26Six to eight more patients than UBS and consensus expectations.
• Potential NSCLC Phase 2 dataset~80 patients; ~25% ORR; >12 months median DORUBS expects potential data in 4Q26, without company guidance on timing.
• Prior sarcoma result50% ORRFrom the first six enrolled patients; longer follow-up is expected on 26 October.
• Price targetUS$7.00Based on a 2.4x EV/'30E peak-sales multiple, supported by DCF.
• Forecast stock return-36.3%Includes -36.3% forecast price appreciation and 0.0% forecast dividend yield.

Impact & implications

UBS says the guidance increase improves confidence in the near-term Amtagvi launch, but does not by itself establish the revenue acceleration needed for the longer-term thesis. Durable NSCLC responses could be important for a 2027 sBLA, possible accelerated approval and expansion of Amtagvi's addressable market.

Risks

• Amtagvi's commercial execution in second-line-plus melanoma may be constrained by the need to build manufacturing infrastructure, manufacturing slots and a commercial organization.
• Key pipeline programs, including Amtagvi in first-line metastatic melanoma and second-line-plus NSCLC, could fail clinically.
• Changes in regulatory standards, endpoints, requirements or submission demands could delay approval.
• Novel therapies approved or developed for melanoma and NSCLC could increase competition.

What to watch

• Evidence on authorized treatment-center activation, treatment-center ramp and referral patterns over the next several quarters.
• Potential updated Phase 2 Amtagvi data in second-line-plus nonsquamous NSCLC in 4Q26.
• First-line melanoma and second-line-plus sarcoma updates at ESMO in October, including IOV-COM-202 data on 23 October and sarcoma follow-up on 26 October.
• The approximate 5 November 2026 release of Iovance's 3Q26 earnings report.